Management to Hold Conference Call at 10:00 A.M. EST
JERUSALEM--(BUSINESS WIRE)--Apr. 30, 2013--
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical
development company, announced today that it will release its unaudited
financial results for the quarter ended March 31, 2013 on Tuesday, May
7, 2013, before the U.S. markets open.
The Company will host a conference call on Tuesday, May 7 at 10:00 a.m.
EDT, featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx,
and Philip Serlin, Chief Financial and Operating Officer of BioLineRx.
The conference call will be available via webcast and can be accessed
through the Investor Relations section of BioLineRx’s website at www.biolinerx.com
or at www.kcsa.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-668-9141 from the U.S. or
+972-3-918-0609 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com
or www.kcsa.com. A
dial-in replay of the call will be available until May 10, 2013; please
dial 1-888-295-2634 from the U.S. or +972-3-925-5921 internationally.
About BioLineRx
BioLineRx is a publicly-traded
biopharmaceutical development company. BioLineRx is dedicated to
building a portfolio of products for unmet medical needs or with
advantages over currently available therapies. BioLineRx’s current
portfolio consists of seven clinical stage candidates: BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for
non-surgical removal of skin lesions has completed a Phase I/II study;
BL-7040 for treating inflammatory bowel disease (IBD) has completed a
Phase IIa trial; BL-8040 for treating acute myeloid leukemia (AML) and
other hematological cancers will shortly commence a Phase II study;
BL-1021 for neuropathic pain is in Phase I development; BL-8020 for
hepatitis C (HCV) has commenced a Phase I/II study; and BL-1020 for
schizophrenia. In addition, BioLineRx has five products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases.
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s Office of the Chief Scientist (OCS). The final stage
includes partnering with medium and large pharmaceutical companies for
advanced clinical development (Phase III) and commercialization. For
more information on BioLineRx, please visit www.biolinerx.com,
the content of which does not form a part of this press release.
Source: BioLineRx Ltd.
KCSA Strategic Communications
Garth Russell, 1 212-896-1250
grussell@kcsa.com
or
Todd
Fromer, 1 212-896-1215
tfromer@kcsa.com
or
Tsipi
Haitovsky, Public Relations
+972-52-598-9892
tsipih@netvision.net.il